Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9494710.26442/2075-1753_19.9.122-128ArticlesСтатьиResearch ArticleNonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis: the problem of choice in terms of safety and impact on cartilageНестероидные противовоспалительные препараты в лечении остеоартрита: проблема выбора с учетом безопасности и влияния на хрящChichasovaN. VЧичасоваНаталья Владимировна

д-р мед. наук, проф. каф. ревматологии ИПО

kafedrarheum@yandex.ruI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России15092017199VOL 19, NO9 (2017)ТОМ 19, №9 (2017)12212828122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94947

The article considers in a comparative aspect the influence of nonsteroidal anti-inflammatory drugs on the synthesis of cartilage prostaglandins, on the metabolism of preglygocans and hyaluronan, and on the course and radiologic progression in osteoarthritis. The data on the conservation effect on articular cartilage of preparations, mainly inhibiting cyclooxygenase-2, are shown on the basis of clinical and experimental data, the positive effect of aceclofenac on the synthesis of hyaluronan and proteoglycans with decreasing their degradation, which, taking into account its effectiveness in relation to the main clinical manifestations of osteoarthrosis and good tolerability allows you to recommend it for the treatment of this pathology.

В статье рассматривается в сравнительном аспекте влияние нестероидных противовоспалительных препаратов на синтез простагландинов хряща, метаболизм протеогликанов и гиалуронана, а также на течение и рентгенологическое прогрессирование при остеоартрозе. Отражены данные о сберегающем влиянии на суставной хрящ препаратов, преимущественно ингибирующих циклооксигеназу-2, показано на основании клинических и экспериментальных данных позитивное влияние ацеклофенака на синтез гиалуронана и протеогликанов при уменьшении их распада, что с учетом его эффективности в отношении основных клинических проявлений остеоартроза и хорошей переносимости позволяет рекомендовать его для лечения этой патологии.

aceclofenacnonsteroidal anti-inflammatory drugsosteoarthritisefficacysafetyeffects on cartilageацеклофенакнестероидные противовоспалительные препаратыостеоартритэффективностьбезопасностьвлияние на хрящBijlsma J.W, Berenbaum F, Lafeber F.P. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011; 377: 2115-26.Dawson JI.LI., Linsell L, Zondervan K. et al. Impact of persistent hip or knee pain overall health status in elderly People: a longitudinal population study. Arthr Rheum 2005; 53: 368-74.Bruyere O, Cooper C.C, Pelletier J-P. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Sem Arthr Rheum 2014; 44: 252-63.Adams P.F, Hendershot G.E, Marano M.A. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 1999.Ruoff G. Management of pain in patients with multiple health problems: a guide for the practicing physician. Am J Med 1998; 105 (1B): 53S-60S.Janssen M, Dijkmans B., van der Sluijs F.A. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheum 1992; 31: 747-52.Насонова В.А., Сигидин Я.А. Патогенетическая терапия ревматических заболеваний. М., 1985; с. 58-63.Haskisson E.C. Clinical aspects of chondroprotection. Sem Arthr Rheum 1990; 19: 30-2.Doherty M. Chondroprotection by nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 1989; 48: 619-21.Brandt K.D. The mechanism of action of nonsteroidal anti-inflammatory drugs. J Rheum 1991; 18: 120-1.Ostensen M. Cartilage changes in arthritis do non-steroidal antiphlogistics have positive or negative effects? Tiddsskr-Nor-Laegeforen 1991; 111: 838-40.Manicourt D.H, Pita J.C. Progressive depletion of hyaluronic acid in early experimental osteoarthritis in dogs. Arthr Rheum 1988; 31: 538-44.Sweet M.B, Thonar E.J, Immelman A.R, Solomon L. Biochemical changes in progressive osteoarthrosis. Ann Rheum Dis 1977; 36: 387-98.Thonar E.J, Sweet M.B, Immelman A.R, Lyons G. Hyaluronate in articular cartilage: age-related changes. Calcif Tissue Res 1978; 26: 19-21.Rizkalla G, Reiner A, Bogoch T, Poole A.R. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence of molecular heterogeneity and extensive molecular changes in disease. J Clin Res 1992; 90: 2268-77.Holmes M.W, Bayliss M.T., Muir H. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J 1988; 250: 435-41.Meyer-Carrive I, Ghosh P. Effects of tiaprofenic acid (Surgam) on cartilage proteoglycans in the rabbit joint immobilization model. Ann Rheum Dis 1992; 51: 448-55.Vries B.J, Van der Berg W. Impact of NSAIDS on murine antigen induced arthritis. A light microscopic investigation of anti-inflammatory and bone protective effects. J Rheum 1990; 17: 295-303.Osteoarthritis. Clinical and Experimental aspects. Ed. J.-E.Reginster, J.-P.Pelletier, Y.Henrotin. Springer, 1999.Haskinsson E.C, Berry H, Gishen P. et al. Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. J Rheum 1995; 22: 1941-6.Rashad S, Revell P, Hemingway A. et al. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989; I: 519-22.Howell D.S, Pita J.C, Muller F.J. et al. Treatment of OA with tiaprofenic acid: biochemical and histological protection against cartilage breakdown in the Pond-Nuki canine model. J Rheum 1991; 18 (Suppl. 27): 138-42.Blot L, Marcelis A., Devogelaer J.P, Manicourt D.H. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human articular cartilage. Br J Pharmacol 2000; 131: 1413-21.Ding C. Do NSAIDs affect the progression of osteoarthritis? Inflammation 2002; 131: 1413-21.Dingle J.T. The effect of nonsteroidal anti-inflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis Cartilage 1999, 7: 313-4.Henroitin Y, Reginster J.Y. Invitro differences among nonsteroidal anti-inflammatory drugs in their activities related to osteoarthritis pathophysiology. Ostearthritis Cartilage 1999, 7: 355-7.Makherje P, Rachita C., Aisen P.S, Pasinetti G.M. Non-steroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheimatol 2001; 19: S7-S11.Fernandes J.C, Caron J.P, Martel-Pelletier J et al. Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthr Rheum 1997; 40: 284-94.Pelletier J.C, Lajeunesse D., Jovanovic D.V. et al. Carprofen simultaneously reduces progression on morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. J Rheumatol 2000; 27: 2893-902.Ratcliffe A, Azzo W, Saed-Nejad F. et al. In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage. J Orthop Res 1993; 11: 163-71.Serni U, Manoni A, Benucci M. Is there preliminary in-vivo evidence for an influence of nonsteroidal anti-inflammatory drugs on progression in osteoarthritis? Part II-evidence from animal models. Osteoarthritis Cartilage 1999; 7: 351-2.Mastbergen S.C, Lafeber F.P, Bijlsma J.W. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatologe (Oxf) 2002; 41: 801-8.Hajjaji E.I, Marcells A, Devogelaer J.P., Manicourt D.H. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. J Rheumatol 2003; 30: 2444-51.Mastbergen S.C, Bijlsma J.W, Lafeber F.P. Selective COX-2 inhibition is favorable to human early and late-atage osteoarthritis: a human in vitro study. Osteoarthritis Cartilage 2005; 13: 519-26.Mastbergen S.C, Jansen N.W, Bijlsma J.W, Lafeber F.P. Differetial direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Therapy 2006; 8: R2. DOI: 10.1186/ar1846Collier S, Ghosh P. Comparison of the effects of non-steroidal anti-inflammatory drugs (NSAIDs) on proteiglican synthesis by articular cartilage explant and chondrocytemonolayer cultures. Biochem Pharmacol 1991; 41: 1375-84.Smith R.L, Kajiyama G, Lane N.E. Nonsteroidal anti-inflammatory drugs: effects on normal and interleukin 1 treated human articular chondrocyte metabolism in vitro. J Rheumatol 1995; 22: 1131-7.David M.J, Vignon E., Peschard M.J. et al. Effect of non-steroidal anti-unflammatory drugs (NSAIDs) on glycosyltransferase activity from human osteoarthritic cartilage. Br J Rheumatol 1992; 31 (Suppl. 1): 13-7.Bort R, Ponsoda X, Carrasco.E et al. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996; 24: 834-41.Henrotin Y, de Leval X, Mathy-Harlet M. et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocyres of inflammatory mediators. Inflamm Res 2001; 50: 391-9.Hinz B., Rau T, Auge D. et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74: 222-35.Yamazaki R., Kawai S., Matsuzaki T. et al. Aceclofenac blocks prostaglandine E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmaсol 1997; 328: 181-7.Diaz C., Rodriguez de la Serna A., Geli C. et al. Efficacy and tolerability of aceclofenac versus diclofenacin the treatment of knee osteoarthritis: a multicenter study. Eur J Rheumatol Inflamm 1996; 16: 17-22.Busquier P.M, Calero E., Rodriguez M. et al. Comparison of aceclofenac with piroxicam in the treatment osteoarthritis. Clin Rheum 1997; 16: 154-9.Torri G., Vignati C, Agrifoglio E. et al. Aceclofenac versus piroxicam in the management of osteoarthritis of knee: a double-blind controlled study. Curr Ther Res 1994; 55: 576-83.Ward D.E, Veys E.M, Bowdler J.M. et al. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheum 1995; 14: 656-62.Kornasoff D, Frerick H, Bowdler J.M. et al. Aceclofenac as a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheum 1997; 16: 32-8.Lidburg P.S, Vojnovic J, Warner T.D. COX2/COX1 selectivity of aceclofenac in comparison with celecoxib and rofecoxob in the human whole blood assay. Fifth world Congress of the OARSI, Barselona, Spain, 4-6 October. 2000; 8 (Suppl. B): Th053.Peris F, Bird H.A, Srni U. et al. Treatment compliance and safety of aceclofenac versus standart NSAIDs in patients with common arthritis disorders: a meta-analysis. Eur J Rheum Inflamm 1996; 16 (1): 37-45.Castellsague J, Riera-Guardia N, Calingaert D. et al. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project). Drug Saf 2012; 35 (12): 1127-46. DOI: 0114-916/12/0012-1127Patel P.B, Patel T.K. Efficacy and safety of aceclofenac in osteoarthritis: a meta-analysis of randomized controlled trials. Eur J Rheumatol 2017; 4: 11-8. DOI: 10.5152/eurjrheum.2017.160080Huskisson E.C, Irani M., Murray F. A large prospective open-label, multicenter SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflamm 2000; 17 (1): 1-7.Llorente M.J. Specific types of non-steroidal anti-inflammatory drugs and relative risk of upper gastrointestinal bleeding [abstract]. Br J Rheumatol 1998; 37 (Suppl. 1): 115.Yanagawa A, Endo T., Kusakari K. et al. Endocopic evaluation of aceclofenac-induced gastrointestinal mucosal damage: a double-blind comparison with sodium diclofenac and placebo. Jpn J Rheum 1998; 8: 249-59.Martel-Рelletier J, Cloutier J-M, Pelletier J-P. Effect of aceclofenac and diclofenac on synovial inflammatory factors in human osteoarthritis. Clin Drug Invest 1997; 14: 226-32.Henrotin Y., de Laval X., Mathy-Hartet M. et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res 1997; 25: 314-9.Gonsalez E., de la Cruz C., de Nicola’s R. et al. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994; 41: 171-8.Blanco F.J, Maneiro E., de Toro F.J. et al. Effect of NSAIDs on synthesis of IL-1 receptor antagonist (IL-Ra) by human articular chondrocytes [abstr.]. Osteoarthritis Cartilage 2000; 8 (Suppl. S27).Akimoto H, Yamazaki R, Hashimoto S. et al. 4-Hydroxy aceclofenac suppressed the interleukin-1-induced production of promatrix metalloproteases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol 2000; 401: 429-36.Yamazaki R, Kawai S, Mizushima Y. et al. A mayor metabolite of aceclofenac, 4-hydroxy aceclofenac, suppressed the production of interstitial pro-collafenase|proMMP-1 and pro-stromelysin-1|proMMP-3 human rheumatoid synovial cells. Inflamm Res 2000; 49: 133-8.